[
  {
    "ts": null,
    "headline": "Robinhood, Medtronic, Microsoft: Top Analyst Calls",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Robinhood Markets (HOOD), Medtronic (MDT), and Microsoft (MSFT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=34bf8b474b491de1f12771ca6e60dbeb84328614a5ce737464996d76ff821e18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770652486,
      "headline": "Robinhood, Medtronic, Microsoft: Top Analyst Calls",
      "id": 138514289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Robinhood Markets (HOOD), Medtronic (MDT), and Microsoft (MSFT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=34bf8b474b491de1f12771ca6e60dbeb84328614a5ce737464996d76ff821e18"
    }
  },
  {
    "ts": null,
    "headline": "Oracle gets upgrade and downgrade: Wall Street's top analyst calls",
    "summary": "Oracle gets upgrade and downgrade: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=913c1ed3ca8d51315dfefcf38390dd9ca335d482ceeda469296893bb4dd7bfb8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770647811,
      "headline": "Oracle gets upgrade and downgrade: Wall Street's top analyst calls",
      "id": 138514297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Oracle gets upgrade and downgrade: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=913c1ed3ca8d51315dfefcf38390dd9ca335d482ceeda469296893bb4dd7bfb8"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award",
    "summary": "A recent antitrust verdict against Medtronic (MDT), which includes a jury award of US$381.7 million to Applied Medical, has pushed the stock into the spotlight as investors reassess legal risks and potential business constraints. See our latest analysis for Medtronic. Against the backdrop of the antitrust verdict, Medtronic’s share price has held around US$102.90, with a 30 day share price return of 5.51% and a 1 year total shareholder return of 16.85%. This suggests momentum has been...",
    "url": "https://finnhub.io/api/news?id=881a72b8c2caa7b8e009328db5b9a30d9072a7df7cd94c202f781dd721ca7a3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770646212,
      "headline": "A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award",
      "id": 138515317,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "A recent antitrust verdict against Medtronic (MDT), which includes a jury award of US$381.7 million to Applied Medical, has pushed the stock into the spotlight as investors reassess legal risks and potential business constraints. See our latest analysis for Medtronic. Against the backdrop of the antitrust verdict, Medtronic’s share price has held around US$102.90, with a 30 day share price return of 5.51% and a 1 year total shareholder return of 16.85%. This suggests momentum has been...",
      "url": "https://finnhub.io/api/news?id=881a72b8c2caa7b8e009328db5b9a30d9072a7df7cd94c202f781dd721ca7a3c"
    }
  },
  {
    "ts": null,
    "headline": "Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance",
    "summary": "Medtronic's Q3 outlook hinges on strong Cardiovascular momentum, with revenues projected to be up 7.3% year over year despite softer EPS.",
    "url": "https://finnhub.io/api/news?id=24ba45f6f6daa3c544ee42ca18ff29d74c47fc551a4a024587277a3c0230af81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770642120,
      "headline": "Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance",
      "id": 138515318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic's Q3 outlook hinges on strong Cardiovascular momentum, with revenues projected to be up 7.3% year over year despite softer EPS.",
      "url": "https://finnhub.io/api/news?id=24ba45f6f6daa3c544ee42ca18ff29d74c47fc551a4a024587277a3c0230af81"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic ordered to pay $382m in anticompetitive surgical device lawsuit",
    "summary": "A jury ruled that Medtronic violated multiple antitrust laws over its use of restrictive contracts with healthcare providers for surgical equipment.",
    "url": "https://finnhub.io/api/news?id=559ce73790d2cca9ad7967de9a2c3d60bba66fbc76d34e2cfb41eb882e8f85e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770640988,
      "headline": "Medtronic ordered to pay $382m in anticompetitive surgical device lawsuit",
      "id": 138415764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "A jury ruled that Medtronic violated multiple antitrust laws over its use of restrictive contracts with healthcare providers for surgical equipment.",
      "url": "https://finnhub.io/api/news?id=559ce73790d2cca9ad7967de9a2c3d60bba66fbc76d34e2cfb41eb882e8f85e5"
    }
  },
  {
    "ts": null,
    "headline": "This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=ab48188c95e8c2837363296d134823b449e2a179f2c2041906444df90084ef5a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770629439,
      "headline": "This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday",
      "id": 138423144,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Roblox-Logo-Mobile-App-On-A-Screen-Smart.jpeg?width=2048&height=1536",
      "related": "MDT",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=ab48188c95e8c2837363296d134823b449e2a179f2c2041906444df90084ef5a"
    }
  },
  {
    "ts": null,
    "headline": "Breaking Down Medtronic: 13 Analysts Share Their Views",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=b02c5664db50e5bfbac403b19e9d2e2b135d74fa0eed928b02b2574986f0ef81",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770627661,
      "headline": "Breaking Down Medtronic: 13 Analysts Share Their Views",
      "id": 138615020,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_8.jpg?width=2048&height=1536",
      "related": "MDT",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=b02c5664db50e5bfbac403b19e9d2e2b135d74fa0eed928b02b2574986f0ef81"
    }
  },
  {
    "ts": null,
    "headline": "Needham Upgrades Medtronic to Buy, Announces $121 Price Target",
    "summary": "Needham  analyst Mike Matson   upgrades Medtronic (NYSE:MDT) from Hold to Buy and announces $121 price target.",
    "url": "https://finnhub.io/api/news?id=a4875bc077464f19ffdefa4da83a06fc4441b4a3f2de41073a9f43ea604731a3",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770625739,
      "headline": "Needham Upgrades Medtronic to Buy, Announces $121 Price Target",
      "id": 138615021,
      "image": "",
      "related": "MDT",
      "source": "Benzinga",
      "summary": "Needham  analyst Mike Matson   upgrades Medtronic (NYSE:MDT) from Hold to Buy and announces $121 price target.",
      "url": "https://finnhub.io/api/news?id=a4875bc077464f19ffdefa4da83a06fc4441b4a3f2de41073a9f43ea604731a3"
    }
  }
]